GlassScriptPhysician profile
Monica Rocco
NPI 1285766493
$420.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $26.09 · 2021: $138 · 2022: $12.83 · 2023: $49.82 · 2024: $56.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $73.00 | 2023-2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Astrazeneca Pharmaceuticals LP | $58.89 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $45.06 | 2021 | |
| Amgen INC. | $32.52 | 2021-2023 | Nplate, Vectibix, Xgeva |
| W. L. Gore & Associates, INC. | $32.13 | 2019 | |
| Ethicon US, LLC | $28.86 | 2019 | |
| Abbvie INC. | $26.55 | 2021-2022 | |
| Daiichi Sankyo INC. | $26.09 | 2020 | |
| Tei Biosciences INC | $23.23 | 2019 | |
| Eisai INC. | $20.40 | 2021 | |
| Next Science LLC | $17.94 | 2023 | Surgx, Blastx, Xperience |
| Dova Pharmaceuticals | $14.16 | 2021 | |
| Tactile Systems Technology INC | $12.83 | 2019 | |
| Merit Medical Systems INC | $8.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Rocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.